No abstract

BACKGROUND AND AIMS Elderly population is a vulnerable group, and cardiometabolic risk factors are highly prevalent among them. This situation complicates when the renal function becomes impaired. The aim of this study was to evaluate the association of renal function with cardiometabolic risk factors among the elderly subjects. METHOD This cross-sectional study was conducted among a group of elderly population (>60 years) living in three different elderly residential complexes. Written informed consent was taken from all. Study population underwent detail history taking, physical examination and relevant investigations. Renal function (eGFR) was estimated by CKD-EPIcr formula. Renal (eGFR, Ur ACR), cardiac (blood pressure, BMI, waist/hip ratio) and metabolic risk factors (lipids, albumin, uric acid, HbA1c) were evaluated. All information was recorded in separate case record form. Collected data were checked for errors and then analysed using the statistical software SPSS 16. RESULTS Around 145 subjects were included. About 42% were from 60–65 years of age, 37% from 66–70 years and rest > 70 years. Mean age was 68 ± 5 years with male 52%. Mean eGFR was 71 ± 2 and in male versus female it was 75 ± 22 versus 66 ± 24 mL/min/1.73 m2 (P < .032) . In 20% elderly eGFR was observed < 60 mL/min/1.73 m2. Prevalence of DM, HTN and obesity was 33%, 46% and 9%, respectively. Age (69 ± 5 and 67 ± 5 years, P < .012), waist/hip ratio (1.01 ± 0.16 and 0.97 ± 0.07,  P < .04), serum creatinine (1.6 ± 0.4 and 0.9 ± 0.2 mg/dL,  P < .001), urinary ACR (320 ± 565 and 82 ± 213 mg/g,  P < .001) were significantly altered among patients with impaired renal function (<60 versus >60 mL/min). CONCLUSION This study showed that various cardiometabolic risk factors among elderly patients are significantly higher in those with impaired renal function.

BACKGROUND AND AIMS The role of cardiac biomarker, NT-pro-BNP and its rising over time may identify chronic kidney disease (CKD) patients at increased risk of cardiovascular morbidity and mortality. Additionally, this may be correlated with altered cardio-metabolic risk factors predicting adverse outcomes. In this study, serum NT-pro-BNP level at different stages of CKD patients was measured to observe its association with different cardiac and metabolic risk factors METHOD This was a cross-sectional study carried out on stable CKD patients, stages 1–5, attending the outpatient department of a tertiary renal care facility. Serum creatinine, estimated glomerular filtration rate (eGFR) and urinary ACR were measured as renal function tests. While cardio-metabolic risk factors included blood pressure, body mass index (BMI), lipid profile, serum albumin, uric acid and hsCRP. Statistical analyses of the results were obtained by using window-based computer software devised with Statistical Packages for Social Sciences (SPSS-22). RESULTS Patients of CKD 5 (30%), stage 4 (23%), stage 3 (26%), stage 2 (18%) and in stage 1 (6.7%) included 149 subjects. In stages 1–5 respectively, they were matched for age 48 ± 12, 48 ± 12, 51 ± 14, 50 ± 12, and 50 ± 11 years, (P = NS); BMI 24 ± 0.9 24 ± 1, 24 ± 1, 24 ± 1 and 24 ± 1 kg/m2, (P = NS) and serum creatinine was variable as 1.5 ± 1.5, 1.7 ± 0.7, 2.6 ± 2.0, 3.0 ± 1.6 and 5.7 ± 2.7mg% (P < 0.001). The mean NT-proBNP had a rising pattern in stages 1–5 showing 335 ± 674, 790 ± 1717, 1221 ± 1994, 2875 ± 6139 and 15645 ± 14741 pg/mL, (P < 0.001). There were positive correlations of NT-pro-BNP with serum creatinine (P < 0.001); CKD stages (P < 0.001). TG (P < 0.003); phosphate (P < 0.008) and negative correlation with serum albumin (P < 0.001). CONCLUSION Higher levels of NT-pro-BNP are seen in advancing stages of CKD. The positive association of NT-pro-BNP with lipids, phosphate and negative relation with albumin indicates its possible prognostic value for cardio-metabolic risk assessment.